Last reviewed · How we verify

Icosapent (MND-2119)

Mochida Pharmaceutical Company, Ltd. · Phase 3 active Small molecule

Icosapent (MND-2119) is a Omega-3 fatty acid / Triglyceride-lowering agent Small molecule drug developed by Mochida Pharmaceutical Company, Ltd.. It is currently in Phase 3 development for Hypertriglyceridemia in patients with elevated cardiovascular risk.

Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism.

Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism. Used for Hypertriglyceridemia in patients with elevated cardiovascular risk.

At a glance

Generic nameIcosapent (MND-2119)
SponsorMochida Pharmaceutical Company, Ltd.
Drug classOmega-3 fatty acid / Triglyceride-lowering agent
TargetMultiple lipid metabolism pathways; FFAR1 (GPR40), FFAR4 (GPR120)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Icosapent (EPA) works by increasing EPA levels in the bloodstream, which helps reduce triglyceride synthesis in the liver and promotes triglyceride clearance. It also has anti-inflammatory and antiplatelet properties that may contribute to cardiovascular benefits beyond simple triglyceride lowering.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Icosapent (MND-2119)

What is Icosapent (MND-2119)?

Icosapent (MND-2119) is a Omega-3 fatty acid / Triglyceride-lowering agent drug developed by Mochida Pharmaceutical Company, Ltd., indicated for Hypertriglyceridemia in patients with elevated cardiovascular risk.

How does Icosapent (MND-2119) work?

Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism.

What is Icosapent (MND-2119) used for?

Icosapent (MND-2119) is indicated for Hypertriglyceridemia in patients with elevated cardiovascular risk.

Who makes Icosapent (MND-2119)?

Icosapent (MND-2119) is developed by Mochida Pharmaceutical Company, Ltd. (see full Mochida Pharmaceutical Company, Ltd. pipeline at /company/mochida-pharmaceutical-company-ltd).

What drug class is Icosapent (MND-2119) in?

Icosapent (MND-2119) belongs to the Omega-3 fatty acid / Triglyceride-lowering agent class. See all Omega-3 fatty acid / Triglyceride-lowering agent drugs at /class/omega-3-fatty-acid-triglyceride-lowering-agent.

What development phase is Icosapent (MND-2119) in?

Icosapent (MND-2119) is in Phase 3.

What are the side effects of Icosapent (MND-2119)?

Common side effects of Icosapent (MND-2119) include Bleeding or bruising, Gastrointestinal upset, Fishy aftertaste.

What does Icosapent (MND-2119) target?

Icosapent (MND-2119) targets Multiple lipid metabolism pathways; FFAR1 (GPR40), FFAR4 (GPR120) and is a Omega-3 fatty acid / Triglyceride-lowering agent.

Related